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after chemoradiation could have even 
further improved the survival results, by 
decreasing the risk of local failure.
Fundamentally, this issue is com-
plex and the data and trials examining 
this issue can be rationalized as either 
favoring or not favoring neoadjuvant 
chemoradiation. We believe our original 
contention remains true, that neoadjuvant 
chemoradiation followed by lobectomy is 
appropriate and improves outcomes in a 
select group of patients. Furthermore, we 
also agree with Dr. Jeremic that a chemo-
radiation-alone approach should continue 
to be optimized, including examination 
of the utility of hypofractionated radio-
therapy regimens and the use of targeted 
agents in patients with locally advanced 
disease to further improve local control. 
However, in the current clinical context 
when local failure remains unaccept-
ably high after standard chemoradiation 
alone, surgical resection can still play an 
important role. 
Matthew Koshy, MD
 Radiation and Cellular Oncology
University of Chicago
Chicago, IL
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that the fundamental question of does 
“debulking surgery” improve the prog-
nosis of patients with N2 non–small-cell 
lung cancer, remains unanswered as the 
control group used concurrent chemora-
diation and was potentially skewed with 
regard to performance status, extent/
bulk of tumor and N2 nodes, and stage 
of disease.
The significance in risk-adjusted 
survival difference between neoadjuvant 
+ lobectomy, HR 0.41, and adjuvant + 
lobectomy, HR 0.5, was not commented 
on. The same applies to patients who 
underwent pneumonectomy. This makes 
it difficult to substantiate the conclusion 
that neoadjuvant therapy is a superior 
mode of treatment for patients with N2 
disease.
As pointed out by the authors the 
selection of treatment, bulky versus 
nonbulky N2 disease, lobectomy versus 
pneumonectomy, left pneumonectomy 
versus right pneumonectomy cannot be 
adjusted for in a retrospective analy-
sis despite elegant statistics, and thus 
strengthens the argument for a random-
ized prospective study. We thank Koshy 
et al. for their insightful analysis and 
comment in a very large series.
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non–small-cell lung cancer. Their arti-
cle, however, raises a number of issues 
that potentially need to be addressed.
Eliminating patients who did not 
survive 4 months to avoid violating the 
proportionality hazard requirements 
for Cox analysis potentially introduces 
a significant error in analysis. Surgical 
mortality or neoadjuvant chemoradia-
tion can be as high as 50%,2 which usu-
ally occurs in the first 4 months after 
initiation of treatment. The use of Cox–
Aalen regression would have allowed 
their inclusion, because of the time-
varying nature of the hazard ratio (HR) 
with this extension of Cox regression 
analysis technique,3 potentially elimi-
nating this as a source of error.
The finding that lobectomy 
patients have a significantly higher 
survival compared with pneumonec-
tomy patients, confirms previous work 
in Europe, revealing essential identi-
cal 5-year survival figures,4 in patients 
undergoing resections for non–small-
cell lung cancer with microscopic N2 
disease. However, this was also a retro-
spective nonrandomized analysis.
Previous work on survival in 
patients with N2 disease who have 
undergone surgery4 identified age, 
positron emission tomography scan-
ning (era of surgery), body mass index, 
laterality, and squamous carcinoma 
histology as additional factors to lobec-
tomy or pneumonectomy as significant 
covariates influencing survival. The 
effect on long-term survival of a posi-
tive resection margin is debated,5 in the 
setting of N2 disease, however, none 
of these variables were included in the 
Cox regression analysis.
In the setting of N2 disease, sur-
gery is essentially a debulking pro-
cedure, as the chance of cure without 
oncological management—neoadjuvant 
or adjuvant is slim. I am of the opinion 
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To the Editor:
Koshy et al.1 provide important 
information on the role of neoadju-
vant versus adjuvant therapy in the 
setting of N2 disease in patients with 
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